68 Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma: Implications for radiotherapeutic management in 121 patients

Stefan A. Koerber, Leon Will, Clemens Kratochwil, Matthias F. Haefner, Hendrik Rathke, Christophe Kremer, Jonas Merkle, Klaus Herfarth, Klaus Kopka, Peter L. Choyke, Tim Holland-Letz, Uwe Haberkorn, Juergen Debus, Frederik L. Giesel

    Research output: Contribution to journalArticle

    20 Scopus citations

    Abstract

    The present study analyzed the impact of 68 Ga-labeled prostate-specific membrane antigen-HBED-CC ( 68 Ga-PSMA-11) PET/CT on radiotherapeutic management in a large cohort of men with primary or recurrent prostate cancer. Methods: This study investigated 121 men with carcinoma of the prostate who underwent 68 Ga-PSMA-11 PET/CT as well as conventional imaging. Fifty patients were treatment-naive, 11 had persistent prostate-specific antigen (PSA) soon after surgery, and 60 presented with recurrent PSA after definitive therapy. Changes in TNM classification of malignant tumor stage (TNM) and radiotherapeutic management after 68 Ga-PSMA-11 imaging were compared with results achieved with conventional imaging. Results: In total, a change in TNM stage and radiotherapeutic management was observed for 49 patients (40.5%) and 62 patients (51.2%), respectively. In treatment-naive patients, a change in TNM stage and radiotherapeutic plan occurred in 26.0% and 44.0% of the cohort, respectively. For patients with PSA persistence or recurrence, TNM and radiotherapeutic management changed in 50.7% and 56.3%, respectively. Conclusion: 68 Ga-PSMA-11 PET/ CT may shortly become an indispensable tool for detecting prostate cancer lesions in treatment-naive patients as well as in men with recurrent disease or persistent PSA and seems to be helpful in personalizing radiotherapeutic management to the individual patients’ distribution of disease.

    Original languageEnglish (US)
    Pages (from-to)234-240
    Number of pages7
    JournalJournal of Nuclear Medicine
    Volume60
    Issue number2
    DOIs
    StatePublished - Feb 1 2019

    Keywords

    • PET/CT
    • PSMA
    • Prostate cancer
    • Radiotherapy
    • Staging

    ASJC Scopus subject areas

    • Radiology Nuclear Medicine and imaging

    Fingerprint Dive into the research topics of '<sup>68</sup> Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma: Implications for radiotherapeutic management in 121 patients'. Together they form a unique fingerprint.

  • Cite this

    Koerber, S. A., Will, L., Kratochwil, C., Haefner, M. F., Rathke, H., Kremer, C., Merkle, J., Herfarth, K., Kopka, K., Choyke, P. L., Holland-Letz, T., Haberkorn, U., Debus, J., & Giesel, F. L. (2019). 68 Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma: Implications for radiotherapeutic management in 121 patients. Journal of Nuclear Medicine, 60(2), 234-240. https://doi.org/10.2967/jnumed.118.211086